Sunshine Biopharma (SBFM) Accounts Payables (2010 - 2026)

Sunshine Biopharma has reported Accounts Payables for 16 years, with the latest figure at $5.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 1.6% year-over-year to $5.1 million; the trailing twelve-month figure through Mar 2026 stood at $5.1 million (up 1.6% YoY), and the FY2025 full-year result was $5.7 million, up 2.19% from the prior year.
• Accounts Payables for Q1 2026 stood at $5.1 million, down from $5.7 million in the prior quarter.
• The five-year high for Accounts Payables was $6.1 million in Q3 2025, with the low at $95234.0 in Q1 2022.
• Historically, Accounts Payables has averaged $3.4 million across 5 years, with a median of $3.6 million in 2024.
• The largest YoY upside for Accounts Payables was 6426.94% in 2022 against a maximum downside of 35.9% in 2022.
• Sunshine Biopharma's Accounts Payables stood at $2.8 million in 2022, then dropped by 7.75% to $2.6 million in 2023, then soared by 114.39% to $5.5 million in 2024, then increased by 2.19% to $5.7 million in 2025, then retreated by 9.88% to $5.1 million in 2026.
• The last three Accounts Payables figures came in at $5.1 million (Q1 2026), $5.7 million (Q4 2025), and $6.1 million (Q3 2025), per Business Quant data.